Hypertesive Patient in Hokuriku area research of Candesartan

Hypertesive Patient in Hokuriku area research of Candesartan - HAKUSAN

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001661

Enrollment

500

Registered

2009-01-28

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

candesartan other ACE-I and/or ARB

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) outpatient whose resting BP is not achieved 135/80 (2)whose hypertension is treatment naive or treated by ACE-I and/or ARB (3)who is eligible for written consent

Exclusion criteria

Exclusion criteria: whose hypertension is treated by other agents rather than ACE-I and/or ARB

Design outcomes

Primary

Measure	Time frame
decreament of heart rate	—

Secondary

Measure	Time frame
decreament of BNP achievement of targeted BP variation of serum K and Cr	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026